Phase 3 results of imatinib for newly diagnosed patients with CML. (A) The results shown are for newly diagnosed chronic phase patients with a median follow-up of 18 months. (B) The 5-year survival curve for newly diagnosed patients with chronic-phase CML treated with imatinib. Shown is the overall survival among patients treated with imatinib based on an intention-to-treat analysis.⁵⁰  Illustration by A. Y. Chen.